Table 3.
Main clinical findings after 6 years of follow up
| Variables | Tol group | CNI group | MMF group |
P value |
|
| 6 yr | 6 yr | 6 yr | Tol vs CNII | Tol vs MMFF | |
| Patients (n) | 10 | 21 | 15 | ||
| Death (n) | 0 | 1 | 0 | ||
| ALT (IU/L) | 71.1 ± 54.2 | 53.9 ± 33.7 | 59.4 ± 45.6 | NS | NS |
| Creatinina | 1.3 ± 0.5 | 1.28 ± 0.5 | 1.7 ± 1.6 | NS | NS |
| Cholesterol | 153.6 ± 55.2 | 161.9 ± 43.2 | 155.9 ± 30 | NS | NS |
| Triglycerides | 130.6 ± 64.1 | 125.4 ± 45.6 | 121.8 ± 39.8 | NS | NS |
| HCV-RNA > 500000 IU/mL | 70 | 42.8 | 46.6 | NS | NS |
| Recurrent infections1 | 0 | 42.8 | 40 | 0.029 | 0.019 |
| Cardiovascular diseases | 50 | 23 | 6.6 | NS | NS |
| Diabetes | 30 | 33 | 27 | NS | NS |
| Dyslipidemia | 50 | 19 | 13 | NS | NS |
| FPR | -0.019 | 0.32 | 0.02 | 0.02 | NS |
1
Urinary and bronchopulmonary infections. FPR: Fibrosis progression rate; ALT: Alanine aminotransferase; HCV: Hepatitis C virus; CNI: Calcineurin inhibitors; MMF: Mycophenolate; NS: Not significant.